Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 11/2004

01-11-2004 | Original Article

Use of complementary and alternative medicine by patients with breast cancer: observations from a health-care survey

Authors: G. Nagel, H. Hoyer, D. Katenkamp

Published in: Supportive Care in Cancer | Issue 11/2004

Login to get access

Abstract

Goals of the work

The aim of this study was to assess the period prevalence and identify predictors of the use of complementary and alternative medicine (CAM) among women with breast cancer.

Patients and methods

In a cross-sectional study, 263 women participating in a quality of life survey reported on CAM use. Differences between CAM users and nonusers were evaluated using logistic regression.

Results

About 3 years after diagnosis the period prevalence of CAM use among women with breast cancer was 36%. Younger women reported usage of CAM more often than older women. Associations between remote disease, pain and psychosocial variables were found. Involvement in self-help groups and active participation in leisure activities were associated with CAM use; this may indicate differences in the patients’ ability to cope with the disease. Most patients were informed of CAM by a physician.

Conclusions

Involvement in self-help groups and leisure activities were associated with CAM use, indicating differences in the patients’ ability to cope. Further research is necessary to evaluate the safety of CAM and to determine the value of CAM in health care.
Literature
1.
Adler SR, Fosket JR (1999) Disclosing complementary and alternative medicine use in the medical encounter—a qualitative study in women with breast cancer. J Fam Pract 48:453–458PubMed
2.
Bloom JR, Stewart SL, Johnston M, Blanks P (1998) Intrusiveness of illness and quality of life on young women with breast cancer. Psychooncology 7:89–100CrossRefPubMed
3.
Boon H, Stewart M, Kennard MA, et al (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario. Prevalence and perceptions. J Clin Oncol 18:2515–2521PubMed
4.
Burstein HJ, Gelber S, Guadagnoli E, et al (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739CrossRefPubMed
5.
Cassileth BR (1999) Complementary and alternative cancer medicine. J Clin Oncol 17 (11s):44–52
6.
Crocetti E, Crotti N, Montella M, Musso MI (1996) Complementary medicine and oncologists attitudes. A survey in Italy. Tumori 82:539–542PubMed
7.
Downer SM, Cody MM, McCluskey P, et al (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed
8.
Durant JR (1998) Alternative medicine: an attractive nuisance. J Clin Oncol 16:1–2PubMed
9.
Eisenberg DM (1997) Advising patients who seek alternative medical therapies. Ann Intern Med 127:61–69PubMed
10.
Eisenberg DM, Kessler RC, Forster C, Norlock FE, Calkins DR, Deldano TL (1993) Unconventional medicine in the United States. Prevalence, costs and pattern of use. N Engl J Med 328:246–252CrossRefPubMed
11.
Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575CrossRefPubMed
12.
Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer. A systematic review. Cancer 83:777–782
13.
Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky M, Petersen L (1996) Breast cancer survivors. Psychosocial concerns and quality of life. Breast Cancer Res Treat 38:183–199PubMed
14.
Hosmer DW, Lemeshaw S (2000) Applied logistic regression, 2nd edn. John Wiley & Sons, New York
15.
International Union against Cancer (UICC) (1997) TNM classification of malignant tumours, 5th edn. John Wiley & Sons, New York
16.
Koller M, Heitmann K, Kussmann J, Lorenz W (1999) Symptom reporting in cancer patients II. Relations to social desirability, negative affect and self-reported health behaviors. Cancer 86:1609–1620
17.
Koller M, Lorenz W, Wagner K, Keil A, Trott D, Engenhart-Cabillic R, Nies C (2000) Expectations and quality of life of cancer patients undergoing radiotherapy. J R Soc Med 93:621–628PubMed
18.
Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg DM (2000) Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92:42–47CrossRefPubMed
19.
Lerner IJ, Kennedey BJ (1992) The prevalence of questionable methods of cancer treatments in the United States. Cancer 42:181–191
20.
Moschèn R, Kemmler G, Schweigkofler H, et al (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9:267–274CrossRefPubMed
21.
Munstedt K, Kirsch K, Milch W, et al (1996) Unconventional cancer therapy—survey of patients with gynaecological malignancy. Arch Gynecol Obstet 258:81–88CrossRefPubMed
22.
Munstedt K, Entezami A, Wartenberg A, Kullmer U (2000) The attitudes of physicians and oncologists towards unconventional cancer therapies (UCT). Eur J Cancer 36:2090–2095
23.
Nagel G, Schmidt S, Strauss B, Katenkamp D (2001) Quality of life in breast cancer patients. A cluster analytic approach. Empirically derived subgroups of the EORTC-QLQ-BR23—a clinically oriented assessment. Breast Cancer Res Treat 68:75–87CrossRefPubMed
24.
Redler-Hasford E, van Eimern W, Tritschler J (1985) Warum sind Krebspatienten aufgeschlossen für unkonventionelle Behandlungsmethoden? Erfahrungsheilkunde 759–769
25.
Rees RW, Feigel I, Vickers A, Zollmann C, McGurk R, Smith C (2000) Prevalence of complementary therapy use by women with breast cancer. A population-based survey. Eur J Cancer 36:1359–1364
26.
Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed
27.
Söllner W, Maislinger S, DeVries A, Steixner E, Rumpold G, Lukas P (2000) Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance but with active coping behaviour. Cancer 89:873–880
28.
29.
Weis J, Bartsch H, Hennies F, et al (1998) Complementary medicine in cancer patients. Demands, patient’s attitude and psychological belief. Onkologie 21:144–149CrossRef
30.
Zollman C, Vickers A (1999) ABC of complementary medicine. Complementary medicine and the doctor. BMJ 319:1558–1561PubMed
Metadata
Title
Use of complementary and alternative medicine by patients with breast cancer: observations from a health-care survey
Authors
G. Nagel
H. Hoyer
D. Katenkamp
Publication date
01-11-2004
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2004
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0675-5

Other articles of this Issue 11/2004

Supportive Care in Cancer 11/2004 Go to the issue

Original Article

Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer

Review Article

Pulse oximetry in supportive and palliative care

Original Article

Discrepant views of oncologists and cancer patients on complementary/alternative medicine

Letter to the Editor

Peripherally inserted central venous catheter in pediatric hematological patients

Short Communication

A hidden cause of hypokalemic paralysis in a patient with prostate cancer

Original Article

Effect of aerobic exercise and relaxation training on fatigue and physical performance of cancer patients after surgery. A randomised controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits